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INTrODuCTION
On the initiative of the General Board of the Polish So-
ciety of Epileptology, in cooperation with the Polish Ne-
onatal Society, the National Consultant for Neonatolo-
gy and the National Consultant for Paediatrics, a Work-
ing Group was established to develop an expert posi-
tion on breastfeeding by women with epilepsy in Po-
land. These recommendations are needed in medical 
care system so as to help guide management for wom-
en with epilepsy in Poland.
The breastfeeding of newborns of mothers with ep-
ilepsy is one of the interdisciplinary issues that should 
be familiar to all specialist involved in the care of 
a mother and her child during this particularly happy 
period of their lives. The conduct of neurologists, ob-
stetricians-gynaecologists, neonatologists and paedi-
atricians should be in accordance with a well-under-
stood routine, but it should be a “live” document and 
routine so that new information so that it can be mod-
ified and supplemented accordingly. This position paper 
provides an educational, practical and organizational 
aspects. It will allow for the introduction of a uniform 
protocol of conduct in Poland, which in turn will im-
prove the safety of the mother and her child.
The safety of breastfeeding while taking antiepileptic 
drugs (AEDs) is a serious concern for both women with 
epilepsy and their neurologists, obstetricians, neona-
tologists and paediatricians. Confirmation of these di-
lemmas is contained in the report “Practice parameter 
update” of the American Academy of Neurology state-
ment regarding breastfeeding of newborns of mothers 
with epilepsy, which despite the passage of time is still 
valid: “The clinical consequences for the newborn of 
ingesting AEDs via breast milk remain underexplored 
and will continue to produce anxiety in women with 
epilepsy bearing children and all who care for these 
clinical dyads” (Harden et al., 2009).
Due to the limited data on the safety of using AEDs 
during lactation, mothers with epilepsy often receive 
conflicting advice and recommendations about breast-
feeding from their physicians. There is a misconception 
that medicines taken by the mother always accumulate 
in the milk. There are also erroneous opinions that the 
baby’s exposure to possible harmful effects of the drug 
is higher during breastfeeding than during pregnancy. 
Because of the risk of the newborn being exposed to the 
possible adverse effects of AEDs via breast milk, epilepsy 
is still considered as a contraindication to breastfeeding 
regardless of the type of medicine the mother is taking.
A review of the literature indicates a significant de-
gree of divergence of recommendations, which is the 
result of a limited number of studies and somewhat ar-
bitrary findings.
In addition, some mothers are afraid that seizures 
may affect the safety of the breastfed child, and sleep 
disturbance may increase the risk of seizures.
In recent years, there has been much new informa-
tion on this subject, encouraging epileptic mothers to 
breastfeed their newborns (Veiby et al., 2015; Birnbaum 
et al., 2019). “Most epileptologists agree that the known 
benefits of breastfeeding outweigh primarily the theo-
retical risk of exposure to most AEDs,” said Prof. Eliz-
abeth E. Gerard, the lead author of the Maternal Out-
comes and Neurodevelopmental Effects of Antiepileptic 
Drugs (MONEAD) project, during the annual Amer-
ican Epilepsy Society Conference in 2019 (Gerard and 
Pennell, 2019).
AImS AND mETHODS
To facilitate a unified and rational approach to breast-
feeding for women with epilepsy, a group of experts in 
epileptology, neonatology and paediatrics held a joint 
meeting to reach a consensus on optimal treatment 
of women with epilepsy. An ad hoc system was devel-
oped to classify available published evidence and ex-
pert opinions, which was used to evaluate recommen-
dations on various aspects related to counselling, risk 
and safety of breastfeeding. This position paper sum-
marizes the available evidence for the inter-relation-
ship between epilepsy, breastfeeding and offspring. It 
contains recommendations for physicians with regards 
to information and advice related to breastfeeding that 
should be provided to women with epilepsy.
In our opinion, it is advisable to develop a common 
therapeutic protocol for neurologists, neonatologists 
and paediatricians. We would like the prepared pro-
tocol to be present in all neurological, neonatological 
and paediatric wards.
Expert opinions presented in this article are based 
on a review of current literature on breastfeeding strat-
egies by women with epilepsy, as well as on clinical ex-
perience and good medical practice of specialists with 
extensive experience in this subject. Each panellist pre-
sented their comments and the version presented here 
was created after a reaching consensus.
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DISCuSSION
The benefits of breastfeeding for the baby and 
the mother
It is truism to state that breastfeeding ensures optimal 
and comprehensive nutrition for newborns. The bene-
fits of breastfeeding for both the infant and the mother 
have been widely recognized by the World Health Or-
ganization (WHO, 2001). Both WHO (2001) and the 
American Academy of Pediatrics (2012) recommend-
ed exclusive natural feeding for the first six months 
of a child’s life, followed by continuing breastfeeding 
with the gradual introduction of local complementary 
foods, considering them the optimal model for feed-
ing a young child.
According to general population data, approximate-
ly 97% of hospitalised women breastfeed after delivery. 
Furthermore, feeding with an infant formula in the ne-
onatal ward itself occurs in more than half of newborns. 
After the child is discharged home, the share of moth-
er’s food in the infant’s nutrition decreases dramati-
cally. In the 6th month of life, only approximately 38% 
of Polish children are breastfed, and only 4% of them 
are exclusively breastfed (Królak-Olejnik et al., 2017). 
The basis for including complementary feeding is the 
insecurity of mothers about food sufficiency. However, 
some of the reasons for weaning were due to physicians’ 
instructions consequent to concerns whereby undesir-
able medications were being taken by nursing moth-
ers (Królak-Olejnik et al., 2017; Wilińska et al., 2005).
Effective release and maintenance of lactation at 
an optimal level in a woman after delivery depends 
largely on the attitude, knowledge and practical skills 
of medical staff, hospital practices in maternity wards 
and the awareness that many mothers need support 
and practical help in breastfeeding. One of the most 
important success factors in breastfeeding is the deci-
sion the woman makes on this topic while she is preg-
nant. The participation of physicians during pregnan-
cy plays important role in this decision. In this regard, 
reliable knowledge about the actual feeding possibil-
ities when taking medications is particularly needed, 
as well as the careful selection of optimal pharmaco-
therapy based on knowledge about the pharmacologi-
cal properties of drugs.
Breast milk
Milk in the mammary gland is produced in the milk 
epithelium of the lactiferous alveoli. In the first days 
after delivery, the milk epithelial cells form the so-
called loose intercellular bridges. These spaces allow 
the transport of high molecular weight substances, such 
as IgA, lysozyme, lactoferrin and other chemical sub-
stances directly from the mother’s blood to milk. It is 
also possible to transfer large molecule drugs, but due 
to the small volume of food consumed by the child at 
this time, the total dose of the drug for the child is not 
large. After 3–4 days after delivery, these free spaces 
are tightly closed due to the natural decrease in pro-
gesterone concentration and under the influence of en-
dogenous glucocorticosteroids.
This phenomenon determines the high concentra-
tion of protein in the colostrum. Colostrum is a thick, 
yellow discharge present in the mammary glands of 
a woman in the first days after childbirth. It is formed 
during pregnancy, approximately since the 20th week. 
Compared to mature milk, it is characterized by i.a. 
a higher content of protein, secretory immunoglobu-
lin A (sIgA), Na, Cl, lactoferrin, cytokines, chemokines, 
trophic factors and oligosaccharides. It has a higher an-
tioxidant potential than milk at any susequent stage of 
lactation (Ma et al., 2017; Wilińska et al., 2015).
The composition of breast milk is dynamic, and 
changes during different times of the day (more fats at 
night, more carbohydrates during the day) and during 
one suckling act (more lactose in phase I milk, more 
fat in phase II milk). The composition of milk also 
changes at particular stages of lactation (Ballard and 
Morrow, 2013).
During the first 2–4 weeks after delivery, the level of 
milk secretion is adjusted to the needs of the baby (sta-
bilization of lactation). Transitional milk becomes ma-
ture milk. It is bluish, watery and clearer. Its volume in-
creases due to water; its caloric content, lactose and fat 
content also increases, and the protein concentration 
decreases. The task of the suckling child is to main-
tain food secretion at an appropriate level through-
out breastfeeding. This balance between food produc-
tion and the needs of the baby appears around the 6th 
week after delivery.
Mature milk differs in composition from the colos-
trum and the transitional milk. Table 1 presents a com-
parison of the concentration of selected milk compo-
nents at various stages of lactation.
Many milk ingredients determine the specific im-
munity-strengthening and anti-inflammatory proper-
ties – among others: sIgA, lactoferrin, lysozyme, oligo-
saccharides, growth factors and viable breast milk cells.
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The benefits of breastfeeding for the mother
Attaching the baby to the breast and releasing lacta-
tion accelerates the involution of the uterus after de-
livery, reduces vaginal bleeding and reduces the risk 
of postpartum anaemia. Lactation has a beneficial ef-
fect on a woman’s metabolism, mainly in the field of 
glucose and lipids, significantly reducing the risk of 
type II diabetes and cardiovascular diseases (Chowd-
hury et al., 2015).
Breastfeeding reduces the risk of pre-menopausal 
breast and ovarian cancer (Collaborative Group on 
Hormonal Factors in Breast Cancer, 2002).
Shortened breastfeeding time is associated with per-
inatal depression, with this effect being bilateral (Di-
asn and Figueiredo, 2015).
Exclusive breastfeeding delays the resumption of 
normal ovulation and fertility, possibly due to elevat-
ed prolactin levels. This method is a highly effective 
global contraceptive program with 98.5–100% effec-
tiveness (Peterson et al., 2000).
Breastfeeding strengthens the bond between the 
mother and the child, which is associated with a cyclic 
release of endogenous oxytocin in the mother (Galbal-
ly et al., 2011).
The benefits of breastfeeding for the child
Breastfeeding improves the survival rate of newborns 
and children up to 5 years old (Sankar et al., 2015). In 
particular, breastfeeding reduces the number of deaths 
due to diarrhoea, especially in areas of the world with 
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Table 1. Differences in composition of transitional and mature breast milk




























































































low economic status (Lamberti et al., 2011; Hauck et 
al., 2011).
Naturally fed newborns less often suffer from infec-
tious diseases, demonstrating the so-called dose-de-
pendent effect. Breastfeeding reduces the incidence of 
respiratory infections caused by the respiratory syncy-
tial virus (RSV), pneumonia, regardless of its aetiolo-
gy, otitis, and gastrointestinal diseases. This beneficial 
effect of breastfeeding persists until the child’s school 
period (Shi et al., 2015; Li et al., 2014).
Data from epidemiological studies indicate a lower 
incidence of many chronic diseases in breastfed infants. 
These diseases include type I diabetes, chronic intes-
tinal diseases, childhood leukaemia and dental caries 
(Patelarou et al., 2012; Amitay and Keinan-Boker, 2015; 
Tham et al., 2015).
Natural feeding reduces the risk of allergic diseases 
(Lodge et al., 2015).
Breastfeeding reduces the risk of obesity in school-
age children, i.a. by affecting the appetite-regulat-
ing hormones such as ghrelin, leptin, and adiponec-
tin. These substances reduce fat deposits and improve 
energy utilization (Horta et al., 2015; Kon et al., 2014).
Breastfeeding is associated with a higher intelligence 
quotient in children. It improves neurodevelopmental 
indicators in premature newborns (Vohr et al., 2006).
In the premature baby population, similarly to the 
full-term babies, natural feeding improves surviv-
al. It statistically significantly reduces the incidence 
of necrotizing enterocolitis (NEC) and nosocomial 
infections.
The incidence and severity of retinopathy of prema-
turity and bronchopulmonary dysplasia, the indicators 
of the quality of care for premature newborns, are sig-
nificantly lower. The degree of this reduction depends 
on the length and exclusiveness of breastfeeding (Zhou 
et al., 2015; Sullivan et al., 2010).
Pharmacokinetics of antiepileptic drugs and 
bioavailability of the drug for the child
When encouraging women with epilepsy to breastfeed, 
caution should always be exercised and the possible ad-
verse effects on the newborn, which could be due to the 
direct effects of AEDs that pass into the breast milk, 
should be assessed.
Data on the use of AEDs by nursing women mostly 
come from small case series and case reports, and ad-
ditionally are dispersed in various databases. Davan-
zo et al. (2013) collected available data for each AED 
from databases such as Hale’s “Drugs and Breast Milk” 
(2012), LactMed (2013), National Library of Medicine 
and MedLine Search (until 2013). When developing 
pharmacokinetic data, we also used the latest literature, 
including Hale’s Medications and Mothers’ Milk (2019), 
Drugs and Lactation Database (2018–2020 update), as 
well as the SmPCs of individual medicinal products.
Based on the available data, we present basic infor-
mation on the pharmacokinetics of AEDs which will 
allow a more complete view of the safety of their use 
by mothers with epilepsy breastfeeding their children.
Pharmacokinetic parameters of antiepileptic drugs
•	 The concentration of the drug in the mother’s blood 
– passive transport is the basic mechanism of drug 
permeation from the mother’s blood to her milk and 
through the placental barrier to the foetus. The con-
centration of the drug in the mother’s blood is the 
most important factor determining the degree of ex-
cretion in milk. There is continuous bi-directional 
drug transport aiming to equalize its concentration 
in both of these compartments.
•	 The concentration of the drug in the mother’s blood 
is modified by its distribution to various tissues and 
organs of the body. A large volume of distribution is 
associated with a rapidly decreasing concentration of 
the drug in the mother’s blood and thus in her milk.
•	 Lipid solubility – lipophilicity is a factor that facili-
tates the transport of the drug through phospholip-
id barriers and into the breast milk fat.
•	 Binding to maternal plasma proteins – transport of 
the drug to milk depends on the degree of its binding 
to maternal plasma proteins. Only the free drug frac-
tion diffuses through biological barriers. The frac-
tion highly bound to the plasma proteins remains in 
circulation without reaching significant concentra-
tions in tissues and other fluids.
•	 Molecular weight (MW) – the size of the molecule is 
a strong determinant of both the drug transfer from 
mother’s plasma to milk and the absorption from the 
child’s digestive tract into its circulation. Low mo-
lecular weight drugs (< 200 g/mol) easily permeate 
from the blood vessel endothelium and the lactifer-
ous alveoli epithelium into breast milk. Drugs with 
a large molecule hardly cross the lipid barrier of the 
cell membrane, which is inherently associated with 
blocking the drug’s access to breast milk.
•	 The degree of ionization – only the nonionized form 
of the drug overcomes biological barriers. Milk 
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is more acidic (pH approx. 7.2) than the mother’s 
blood (pH approx. 7.4). This difference promotes the 
easy penetration of alkaline drugs into milk. These 
preparations fall into the so-called ionic trap, accu-
mulating in the breast milk. Conversely, organic ac-
ids remain ionized and tend to persist in the moth-
er’s circulation.
•	 Half-life t 0.5 – the shorter the better. Preferred are 
drugs with a t 0.5 of 1–3 hours.
•	 t max – time from taking the drug to reaching the max-
imum concentration (C max) in the mother’s blood. 
During the period of the highest concentration of 
the drug, the mother should not breastfeed.
•	 pKa – pH value at which there is a balance between 
the ionized form and the non-ionized form of the 
drug. In general, drugs diffuse freely between the 
mother’s milk and blood, remaining in balance of 
concentration. It is a protective mechanism prevent-
ing the accumulation of the drug in the lactiferous 
alveolus. Low pKa means the possibility of a return 
from the milk to the mother’s plasma according to 
the current concentration difference. A drug that 
has a pKa higher than 7.2 does not undergo typical 
diffusion back into the mother’s plasma, i.e. it is se-
questered in the milk.
Bioavailability
The bioavailability of a drug for a child is determined 
by the following parameters:
•	 RID (Relative Infant Dose). The drug dose the child 
receives during breastfeeding is the product of the 
concentration of the drug in mother’s milk (Cm) 
and the volume of milk consumed by the child per 
day (Vm). Drugs with RID < 10% are generally safe.
•	 M/P ratio – the ratio of milk concentration to the 
maternal plasma concentration. The safe M/P ratio 
is < 1. M/P ratio > 1 indicates high penetration into 
milk. When assessing its size, it should be remem-
bered that even when its value exceeds 1, the total 
daily dose taken by an infant with breast milk is al-
most always significantly lower than the therapeutic 
dose in infants (Verstegen et al., 2015). On the other 
hand, if the concentration in the plasma is low, the 
total dose of the drug taken by the child is small, al-
though the ratio may be high.
•	 PPB ratio (maternal protein binding) – means the 
degree of binding of the drug to maternal plasma 
proteins. High binding to maternal plasma albu-
mins results in poor drug excretion into breast milk.
•	 The volume of distribution (Vd) is the space of 
a woman’s body other than blood into which the drug 
permeates. The low volume of distribution indicates 
a very short drug presence in the body. In combina-
tion with a very short half-life, this means very fast 
elimination of the drug from the body.
•	 Oral bioavailability, i.e. absorption from the gastro-
intestinal tract, where the term “poor” means low ab-
sorption of the drug from milk through the child’s 
digestive tract into their blood.
Conclusion
Drug transfer to breast milk increases if the drug:
•	 reaches high maternal serum levels
•	 has a low molecular weight
•	 is poorly bound to plasma proteins (high drug free 
fraction)
•	 is lipophilic and easily crosses phospholipid mem-
branes.
Pharmacokinetic parameters associated with high bio-
availability of the drug for the child include:
•	 high relative dose of the drug (RID)
•	 long biological half-life
•	 high M/P ratio (not always)
•	 high distribution volume
•	 extended t max
•	 high pKa
Pharmacokinetic and physicochemical properties 
of individual antiepileptic drugs (according to Hale, 
2019; Davanzo et al., 2013; Veiby et al., 2015) as well 
as lactation risk assessment (according to Hale, 2019; 
Drugs and Lactation Database) are presented in ta-
bles 2, 3 and 4.
Clinical parameters assessing the safety of AED 
during lactation
In addition to the pharmacokinetic parameters of 
AEDs presented and discussed earlier, when assessing 
the safety of these drugs, it is worth to analyse clinical 
parameters such as:
1. Theoretical Infant Dose (TID), the theoretical dose in 
a newborn – is the maximum estimated amount of 
drug taken with breast milk; in other words, it is an 
estimate in milligrams per kilogram of the theoreti-
Joanna Jędrzejczak et al.
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cal daily dose for the infant (according to the Atkin-
son formula: TID = daily mother’s milk consump-
tion (150 ml/kg/day) × maximum concentration of 
the drug in the mother’s milk) (Atkinson et al., 1988).
2. The therapeutic dose in the neonatal period – the ther-
apeutic dose in mg/kg/day, used in therapy during 
infancy. By comparing the TID dose with the ther-
apeutic dose, the safety of the drug can be assessed. 
The therapeutic dose, which is higher than TID, en-
sures the safety of drugs during breastfeeding (Ta-
bles 5 and 6).
Davanzo et al. (2013) proposed 3 categories of drugs 
used during breastfeeding, i.e. safe: carbamazepine 
(CBZ), phenytoin (PHT), phenobarbital (PB), prim-
idone (PRM), valproic acid and its salts (VPA); con-
traindicated: clonazepam (CLN), diazepam (DZP), 
ethosuximide (ESM), zonisamide (ZNS) and moder-
ately safe: lamotrigine (LTG), gabapentin (GBP), leveti-
racetam (LEV), oxcarbazepine (OXC), tiagabine (TGB), 
topiramate (TPM), vigabatrin (VGB), lacosamide 
(LCM). The latter category has a less well documented 
safety profile due to the limited clinical experience and 
lack of research. These drugs can be used with caution. 
The mother should use the lowest dose possible. The 
infant should be monitored and, if possible, the con-
centration of the drug should be determined in the se-
rum of the child. Two drugs, PB and PRM, which Da-
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Table 2. Lactation risk categories (Hale, 2019)
L1 Safest (compatible). Controlled studies in breastfeeding women have shown no negative effect on the child. Usually, non-
absorbable drugs with low bioavailability
L2 Safer (probably compatible). No harmful effects found. Safety identified in small human studies. Breastfeeding is allowed
L3 moderately safe (probably compatible). There are no controlled human studies. Some studies indicate a possible biological drug 
effect on the child. To be used, if the benefits outweigh the risks. This category covers all new, uncharted drugs
L4 Potentially hazardous. Documented risk for child or lactation. To be used if they are necessary for the mother and cannot be 
replaced by other drugs
L5 Hazardous. Significant harmful effects of the drug on the child, documented in human studies. Contraindicated in lactation
Table 3. Old generation antiepileptic drugs (AEDs) – pharmacokinetic and physicochemical characteristics and lactation 
risk categories
AED t 0.5 [h] t max [h] BA [%] mW  
[g/mol]
rID [%] m/P PPB [%] Vd 
[L/kg]




 6–10 children 
1–4 100 144 0.99–5.6 0.1–1.4 
(mean 0.42)









mean 0.94 <10 0.72 9.3 L4
PHT 7–42 
(mean 22)
4–12 70–100 252 0.6–7.7 0.18–0.45 89 0.52–1.19 8.3 L2







100 236 3.8–5.9 0.69 70–80 08–1.8 7 L2





1–2 100 285 0.88–7.14 0.2–2.7 
(mean 0.5)
99 0.7–2.6 3.4 L3
PB 53–140 2–4 80–100 232 24 04–0.6 45–60 adults
3–43 newborns
0.5–0.6 7.2 L4
t 0,5 – half-life; t max – time to maximum drug concentration; BA – bioavailability after oral administration; MW – molecular weight; RID – relative infant 
dose; M/P – milk to plasma ratio of a drug concentration; PPB – plasma protein binding; Vd – volume of distribution; pKa – the negative logarithm of 
the ionization constant of an acid
VPA – Valproic acid; CBZ – Carbamazepine; PHT – Phenytoin; DZP – Diazepam; PB – Phenobarbital; ESM – Ethosuximide
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Table 4. New generation antiepileptic drugs (AEDs) – pharmacokinetic and physicochemical characteristics and lactation 
risk categories 
AED t 0.5 [h] t max [h] BA [%] mW [g/mol] rID [%] m/P PPB [%] Vd [L/kg] pKa Hale’s (2019) 
lactation risk 
categories
 LTG 14–103 




98 256 9.2–18.27 0.057–1.47 55 09–1.3 5.7 L2
OXC 1.3–2.3 (OXC)
9 (MHD)






100 170 3.4–7.8 1 <10 0.5–0.7 _ L2
LCM 13 1–4 100 250 NA NA <15 0.6 12.47 L3
LTG – Lamotrigine; OXC – Oxcarbazepine; LEV – Levetiracetam; LCM – Lacosamide
t 0,5 – half-life; t max – time to maximum drug concentration; BA – bioavailability after oral administration; MW – molecular weight;  
RID – relative infant dose; M/P – milk to plasma ratio of a drug concentration; PPB – plasma protein binding; Vd – volume of distribution;  
pKa – the negative logarithm of the ionization constant of an acid; NA – no data 
Table 5. Clinical parameters assessing the safety of older generation AEDs during lactation (Davanzo et al., 2013; Hale, 2019)
AED TID [mg/kg/day] Oral therapeutic dose in infants 
[mg/kg/day]
rID [%] Hale’s (2019)  
lactation risk categories
Drug safety
CBZ 0.7 10–20 3.8–5.9 L2 safe
CLN 0.002 0.1–0.2 2.8 L3 contraindicated
DZP 0.05 iv. 0.1–0.3 po. 0.5–1 0,88–7.14 L3 contraindicated
PHT 0.4 5–8 0.6–7.7 L2 safe
ESm 11.5 15–40 31.4–73.5 L4 contraindicated
PB 0.4 3–4 24 L4 moderately safe 
Prm 0.9 12–20 8.4–8.6 L4 moderately safe 
VPA 0.7 limited data in the neonatal 
period available
0.99–5.6 L3 safe
TID – theoretical infant dose; RID – relative infant dose
CBZ – Carbamazepine; CLN – Clonazepam; DZP – Diazepam; PHT – Phenytoin; ESM – Ethosuximide; PB – Phenobarbital; PRM – Primidone;  
VPA – Valproic acid
Table 6. Clinical parameters assessing the safety of new generation AEDs during lactation (Davanzo et al., 2013; Hale, 2019)
AED TID [mg/kg/day] Oral therapeutic dose in 
infants [mg/kg/day]
rID [%] Hale’s (2019) lactation risk categories Drug safety
GBP 1.7 10–15 (orly pediatric dose 
available)
1.3–6.6 L2 moderately safe 
LTG 0.7 1–6 with valproic acid 
5–15 with enzyme inducing 
AEDs
9.2 L3 moderately safe 
LEV 3.9 5–10 3.4–7.8 L3 moderately safe 
OXC b.d. 27.7–50 (< 18 years) 1.5–1.7 L3 moderately safe 
TGB b.d. <12 years limited data available NA L3 moderately safe 
TPm 0.3 1–6 (< 2 years) 24.5 L3 moderately safe 
VGB 0.1 25–50 1.5–2.7 L3 moderately safe 
ZNS 1.9 5–8 28.9–36.8 L4 contraindicated
GBP – Gabapentin; LTG – Lamotrigine; LEV – Levetiracetam; OXC – Oxcarbazepine; TGB – Tiagabine; TPM – Topiramate; VGB – Vigabatrin;  
ZNS – Zonisamide
TID – theoretical infant dose; RID – relative infant dose
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vanzo et al. (2013) listed as safe during lactation, are 
described by other authors as moderately safe (Ander-
son, 2010) or potentially risky (Hale, 2019) due to the 
extremely long half-life and accumulation in the body 
of an infant. These drugs are currently very rarely used.
Moderately safe new generation drugs
Lamotrigine
LTG may accumulate in the blood of an infant due to the 
relatively large fraction of the drug not bound to plas-
ma proteins and the metabolism occurring through glu-
curonidation, which in the child reaches full efficiency 
only around 20 months of age (Miyagi et al., 2007). Both 
blood concentrations and half-life (14–103 hours) show 
large inter-individual differences. Polytherapy also af-
fects t 0.5. It is shortened by the combination with CBZ 
or PHT (adults – 14; children – 7; newborns and infants 
– 23 hours), while it extends the use of VPA (70, 45–50 
and 136 hours, respectively).
During pregnancy, the drug reaches only slight-
ly lower levels in the umbilical cord blood than in the 
mother’s blood (a reduction of approx. 16% on average). 
The reduction in maternal milk concentration is great-
er (by 33% on average), and in the baby’s blood by as 
much as 77% (according to various studies 15–45% of 
the mother’s concentration).
Although the drug concentration in milk is described 
as relatively high, in most studies there are no reports 
of obvious abnormalities in breastfed infants (Ohman 
et al., 2000; Page-Sharp et al., 2006). A case of adverse 
reaction related to LTG exposure via mother’s milk 
was reported in a 16-day-old newborn whose mother 
had the lamotrigine dose significantly increased dur-
ing pregnancy (from a 450 mg/d dose to 875 mg/d) 
due to numerous seizures. On the 9th day after deliv-
ery, the mother showed toxic symptoms (concentration 
was not measured). The patient continued to feed un-
til day 16, when the newborn had a severe apnoea inci-
dent (Nordmo et al., 2009). Cases of mild thrombocy-
tosis (Drugs and Lactation Database) and withdrawal 
syndrome (Anderson, 2020) have also been reported.
Due to the observed large differences in the concen-
tration of the drug in the blood of breastfed children at 
similar levels in the blood of mothers, the effect of ge-
netic factors on the drug’s metabolism has been sug-
gested. This leads to the recommendations of some 
authors regarding the control of drug concentration 
in the blood of breastfed infants (Liporace et al., 2004).
The concentration of the drug in the milk decreas-
es with the duration of lactation. A Norwegian study 
documents that the development of children born to 
mothers with epilepsy receiving LTG during pregnan-
cy is better if they were breastfed after birth, compared 
to the control group of babies born from mothers who 
were artificially fed since birth. Development in cate-
gories of behaviour, motor skills, social contacts and 
speech were assessed at 6, 18 and 36 months of age. In 
general, the authors found lower development rates of 
children of mothers with epilepsy compared to the ref-
erence group of newborns of healthy mothers. Breast-
feeding reduced these differences. Long-term breast-
feeding (> 6 months), compared to artificial feeding, has 
been associated with accelerated development in all of 
the mentioned categories. The positive effect of breast-
feeding increased with its length (Veiby et al., 2013). 
Similarly, in a 3-year observation of the development 
of children of mothers receiving LTG during pregnan-
cy and lactation, a beneficial effect of long-term breast-
feeding on intelligence (IQ) was observed compared to 
shorter feeding (Meador et al., 2009).
Child monitoring: excessive sedation or irritability; 
reluctance to suckle, malnutrition, small weight gain; 
skin rash. Monitoring of liver enzymes activity and 
morphology as well as monitoring of LTG (Drugs and 
Lactation Database) levels may be indicated for “symp-
tomatic” children.
Oxcarbazepine
The drug is rapidly metabolized to 10-hydroxycarbaze-
pine (MHD) after ingestion, with a much longer half-
life (9 h) than OXC. This metabolite is responsible for 
the antiepileptic activity of the drug. OXC is excreted 
in the urine in the form of metabolites – mainly MHD 
and its glucuronide derivative.
Transplacental transport of OXC occurs very easi-
ly, therefore the concentration of the drug in the blood 
of the pregnant and the foetal blood is almost equal. 
A significant reduction of the drug concentration is 
observed in the milk of lactating women. Due to this, 
from the 5th day after birth, the drug is practically un-
detectable in the blood of newborns (a decrease of 93% 
in relation to cord blood). No adverse effects were not-
ed in the children of mothers using OXC except for 
withdrawal syndrome (Anderson, 2020). Bulau et al. 
(1988) are of the opinion that breastfeeding by patients 
treated with OXC is safe, but according to Hale (2019) 
– due to the lack of data – the drug belongs to category 
L3, i.e. probably safe.
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Child monitoring: excessive sedation or irritability; 
reluctance to suckle, malnutrition, small weight gain; 
diarrhoea. If clinical signs increase, liver enzymes ac-
tivity determination should be considered. In order to 
reduce the risk of coagulologic disorders (the drug af-
fects the metabolism of vitamin K), a newborn at birth 
should, in addition to the standard dose of 1 mg vita-
min K intramuscularly, receive an additional 1 mg of 
vitamin K orally every 3 days in the first 2 weeks of life.
Levetiracetam
The placental transport of the drug occurs easily, lead-
ing to comparable levels in the mother’s blood and the 
umbilical cord blood. Due to the low molecular weight 
and low plasma protein binding, the drug readily pass-
es into breast milk, however the plasma concentrations 
of infants are low.
In a report by Kramer et al. (2002), the authors write 
about the child’s lower activity during feeding, inefficient 
suckling and reduced muscle tone in a child who is breast-
fed by a mother using polytherapy (including LEV). The 
easy penetration of the drug into the blood of the foetus 
and breast milk is confirmed by subsequent reports, how-
ever, they emphasize the rapid elimination of LEV by the 
child’s body. In the subsequent days of life, the concentra-
tion in the child’s blood drops sharply. Already on the 4th 
day after birth, the concentration remains at the detection 
threshold (Tomson et al., 2007; Johannessen et al., 2005).
Child monitoring: doses up to 3500 mg/d should 
not cause high concentration levels of LEV in the milk 
or adverse effects, especially after the child reaches 
2 months of age (Drugs and Lactation Database). How-
ever, attention should be paid to the level of activity of 
the newborn, hyperactivity, activity at the breast, suck-
ling efficiency and feeding efficiency (weight gain).
Lacosamide
Due to its relatively low molecular weight (250 g/mol), 
low plasma protein binding (<15%) and a low volume 
of distribution (0.6 L/kg), the drug may theoretically 
reach significant milk concentrations in lactating wom-
en. There is no accurate data on the permeation of the 
drug into breast milk. Observations to date have shown 
that after the administration of 200 mg/d, LCM reach-
es low levels in the milk, and its use for 7–9 months at 
a dose of 400 mg/day does not adversely affect the de-
velopment of the breastfed infant (Anderson, 2020). 
The drug requires research, and caution should be ex-
ercised during its use by lactating women.
Child monitoring: excessive sedation or irritabili-
ty, suckling weakening, risk of undernutrition, insuf-
ficient weight gain, vomiting and posseting, diarrhoea, 
muscular tremor (Grosso et al., 2014).
In the case of the new generation of moderately 
safe drugs, such as GBP, pregabalin (PGB), TPM, TGB, 
VGB, despite the known safe pharmacokinetic profile, 
there are not enough studies to assess their excretion 
into breast milk. During lactation, infants of mothers 
treated with these drugs – especially in polytherapy – 
should be carefully monitored.
Older generation antiepileptic drugs – contraindicated
Benzodiazepines (BDZ) – DZP and CLN
DZP has a very long half-life (see Table 3). The drug is 
almost completely bound to plasma proteins and me-
tabolized to 3 active compounds excreted in the urine, 
of which desmethyldiazepam has the t0,5 of 30–200 
hours. The concentrations of the drug and its metab-
olite in the milk show individual differences (Wesson 
et al., 1985). Both DZP and its metabolites accumulate 
in the infant’s body, with the premature babies being 
at the greatest risk of toxicity.
There is a similarly long half-life (up to 60 hours) for 
CLN, which can also accumulate in an infant. Most 
authors believe that both DZP and CLN should not be 
used long-term in nursing mothers and only allow their 
single administration. If it is necessary to use BDZ, it is 
preferable to give lorazepam (LZP), which has a shorter 
t0.5 (adults 12–15 hours; infants up to 30 hours), reach-
es very low levels in breast milk and does not accumu-
late (Davanzo et al., 2013; Hale, 2019; Drugs and Lac-
tation, Database; Veiby et al., 2015).
Ethosuximide
The drug’s plasma protein binding is negligible, and the 
half-life varies in children and adults (Table 3). ESM 
is extensively metabolised in the liver via cytochrome 
P450 to inactive metabolites excreted in the urine. The 
amount of ESM excreted into the milk is comparable 
to its concentration in the mother’s blood; the M/P ra-
tio is approximately 1. RID reaches high values (31.4–
73.5%), but Veiby et al. (2015) also report RID = 113%, 
which explains the high concentration in the serum 
of breastfed infants (15–40 mg/l) (Kuhnz et al., 1984).
ESM is considered potentially dangerous during lac-
tation and requires monitoring during breastfeeding. 
Some believe that in nursing women should only be 
used when there is no alternative treatment (Davanzo 
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et al., 2013). Adverse effects included irritability, hyper-
activity, drowsiness, and suckling disorders; in com-
bination with PB or PRM cheiloschisis is mentioned.
Child monitoring: drowsiness, irritability, prob-
lems with suckling, weight loss, observation of psych-
omotor development (especially in premature babies), 
sometimes liver enzymes’ activity may need to be deter-
mined. Monitoring of infant serum concentration dur-
ing breastfeeding is recommended to exclude toxicity.
Older generation antiepileptic drugs – moderately safe
Phenobarbital
It has a very long half-life in children (20–133 hours in 
infants and up to 500 hours in premature babies) (Ta-
ketomo et al., 2012) and a lower plasma protein binding 
in newborns when compared to adults (3–43% vs 51%) 
(Davanzo et al., 2013). This means that it can accumu-
late in newborns and infants. It is partly metabolised 
in the liver by cytochrome P450 enzymes and excret-
ed both in an unchanged form and as metabolites. PB 
permeates into breast milk and reaches varying levels 
in it. In general, concentration levels in infant plasma 
account for 30% of the concentration in the maternal 
plasma (Hale, 2019), however cases have been report-
ed where they have exceeded twice the maternal plas-
ma concentration level.
Maintaining feeding can alleviate any abstinence 
in the newborn baby. Caution should be exercised, es-
pecially in polytherapy and after pausing or stopping 
breastfeeding (risk of convulsions).
Child monitoring: drowsiness, suckling reflex, ad-
equate weight gain and development (especially in 
younger infants and in the case of polytherapy). Mon-
itoring of concentration in the infant’s serum during 
breastfeeding is recommended to exclude toxicity.
Primidone
PRM is mainly metabolised to PB. The M/P ratio is 0.7. 
Serum concentrations of primidone and its metabo-
lites in breastfed infants may be close to the therapeu-
tic range value. The drug should be used with caution 
while breastfeeding, because it can accumulate in the 
body of an infant (Veiby et al., 2015).
Child monitoring: drowsiness, suckling reflex, ad-
equate weight gain and development (especially in 
younger infants and in the case of polytherapy). Mon-
itoring of infant serum concentration during breast-
feeding is recommended to exclude toxicity.
Older generation antiepileptic drugs – safe
Carbamazepine
The drug is extensively metabolised in the liver by cy-
tochrome P450 enzymes to several metabolites that are 
excreted in urine and faeces. CBZ and the pharmaco-
logically active metabolite 10,11-epoxide (CBZ-E) are 
poorly excreted into breast milk, partly due to the high 
plasma protein binding. The M/P ratios of CBZ and 
CBZ-E are 0.69 and 0.79, respectively (Davanzo et al., 
2013). CBZ concentrations in breast milk are moder-
ate and very varied: from 0.34 to 6 mg/L (Shimoyama 
et al., 2000). Other authors note the average concentra-
tions in milk: CBZ – 7.1 mg/L, CBZ-E – 2.6 mg/L (Hale, 
2019). The RID value is low (3.8–5.9%), similar to the 
concentration in the serum of infants, which are usu-
ally below the therapeutic range.
Breastfeeding is considered safe. Adverse reactions 
(somnolence, reduced suckling, rash, sporadic liver dys-
function cases) have rarely been reported.
Child monitoring: drowsiness, irritability, suckling 
problems, weight loss, sometimes liver enzyme activi-
ty determination may be required.
Phenytoin
PHT is considered a safe drug during lactation, be-
cause it binds substantially to plasma proteins (89%), it 
is excreted in breast milk to a small extent (M/P: 0.18–
0.45) and it reaches low concentration levels in it (Hagg 
and Spigset, 2000; Shimoyama et al., 1998; Harden et 
al., 2009). It is metabolized in the liver by cytochrome 
P450 enzymes in hydroxylation and glucuronidation 
reactions, and then it is excreted in the urine, mainly 
in the form of inactive metabolites. The effect of PHT 
on a fed infant is considered to be minimal if maternal 
plasma concentration is <10 mg/L (Hale, 2019).
Extremely rare cases of hyperactivity (probably 
caused by the withdrawal syndrome) and methemo-
globinemia, somnolence and suckling problems have 
been observed in children of mothers using PHT in 
polytherapy with PB or CBZ.
Child monitoring: observation for the mentioned 
adverse reactions.
Valproic acid and its salts
Due to almost complete plasma protein binding, the 
drug very poorly permeates into breast milk, thus en-
suring safety during lactation (Meador et al., 2010). It 
is metabolized in the liver, mainly in the glucuronida-
tion reaction, and excreted in the urine primarily in 
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the form of metabolites. VPA reaches the lowest con-
centration levels in infant blood of all AEDs, i.e. 0.7–
1.5 mg/L (only 0.9–2.3% of maternal blood concen-
tration) (Schaefer et al., 2007). M/P ratio is 0.01–0.3% 
(Veiby et al., 2015). The case of a breastfed infant with 
symptoms of thrombocytopenia, purpura and anaemia 
(Stahl et al., 1997) indicates the need for careful use of 
the drug during breastfeeding, although the relation-
ship with the mother’s VPA intake (Drugs and Lac-
tation Database) has not been completely confirmed. 
Due to the theoretical risk of hepatotoxic effects of the 
drug, an assessment of liver and bile duct function in 
late jaundice is justified.
Child monitoring: drowsiness, irritability, suckling 
problems, weight loss, sometimes liver enzymes activ-
ity determination may be required. Attention should 
also be paid to unusual bleeding.
It should be noted that the potentially adverse effects 
of the drug on the body of a newborn child depends on 
their age. Newborns, especially premature babies, are 
at the highest risk of side effects. This is not only due 
to the “anatomical leaks” of the mammary gland and 
the ability of its metabolism and elimination or excre-
tion. Regarding maternal excretion, the drug elimi-
nation rate for premature babies born between 24–28 
weeks of pregnancy is initially 5%; in premature babies 
born between 28–34 weeks – 10% and in newborns with 
34–40 weeks of gestation, approximately 33%. In a full-
term newborn baby, only after 2 months of life does the 
child’s ability to excrete the drug is identical to that of 
the mother. Hence, the number of complications asso-
ciated with the activity of drugs contained in food is: 
in the first month of life – 67%, while over 6 months of 
age it is only 4% (Berlin and Briggs, 2005).
The current state of breastfeeding of newborns of 
mothers with epilepsy
Many factors influence a mother’s decision to breast-
feed. Socio-economic factors such as the mother’s ed-
ucation, income, employment and social class affect 
both the initiation rate and the duration of breastfeed-
ing (Quigley et al., 2012). Emotions and self-esteem are 
other factors that can influence breastfeeding decisions. 
Women with epilepsy may have higher rates of depres-
sion and anxiety especially during pregnancy and after 
delivery (Reiter et al., 2013). According to Norwegian 
studies, women with epilepsy were more likely to have 
perinatal depression (26.7%) or anxiety (22.4%) than 
women without epilepsy (18.9% and 14.8% respective-
ly, p < 0.001) and women with other chronic diseases 
(23.1% and 18.4% respectively, p = 0.03 and 0.01) (Bjørk 
et al., 2015; Turner et al., 2009).
It is extremely important to know the additional fac-
tors that may prevent one from making the decision to 
start or continue breastfeeding. According to a study 
which attempted to identify the causes of the lack of 
breastfeeding in women with epilepsy, such causes 
were only known in 17.6% of individuals (Al-faraj and 
Pang, 2019). These included the aforementioned fear of 
exposing the child to AEDs through breast milk, rec-
ommendations of medical staff (neurologists, obstetri-
cians, neonatologists and paediatricians) not to breast-
feed and technical difficulties affecting the unsuccess-
ful attempts at breastfeeding and insufficient lactation. 
On the other hand, fear of children being exposed to 
AEDs through breast milk, frequent seizures and in-
sufficient milk were the most common causes of early 
cessation of breastfeeding. Mothers with epilepsy who 
gave birth on time and whose seizures were controlled 
were more likely to engage in long-term breastfeeding. 
It seems that family support and clear advice from doc-
tors can greatly enhance decision making with regards 
to breastfeeding.
The results of these studies also showed that a conver-
sation with a neurologist about breastfeeding was con-
ducted with approximately half of women with epilep-
sy (52.95%). However, 91% of patients reported having 
such a conversation with a nurse. Of 66% of the wom-
en who were under maternity care at the Beth Israel 
Deaconess Medical Center, only 13% received a lacta-
tion consultation before delivery compared with 58% of 
the healthy population. It is clear that the education on 
breastfeeding by a neurologist was significantly posi-
tively correlated with the decision on feeding (p  <  0.005) 
and its initiation (p < 0.05). In addition, the postnatal 
lactation consultation was also associated with a sig-
nificantly higher percentage of breastfeeding initia-
tion (p < 0.05), compliance with breastfeeding recom-
mendations after 6 weeks (p = 0.01) and after 3 months 
(p = 0.01) (Al-faraj and Pang, 2019).
The rates of breastfeeding by women with epilepsy 
vary from country to country (Dyson et al., 2005). Ac-
cording to recent US data, women with epilepsy breast-
feed their children less often than women in the gener-
al population (Gerard and Pennell, 2019; Al-faraj and 
Pang, 2019). The feeding initiation rate was 79%. On-
ly 41% of women breastfeed for 3 months (Centers for 
Disease Control and Prevention, 2014).
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The NEAD study shows that a total of 42% of women 
with epilepsy breastfeed for the first three months af-
ter delivery (Meador et al., 2010). The MONEAD study 
(continuation of the NEAD study) confirmed a lower 
percentage of nursing women with epilepsy for the first 
3 months and subsequent 6 months (Gerard and Pen-
nell, 2019; Al-faraj and Pang, 2019). It was shown that 
51% of women with epilepsy (n = 102) started feeding 
after delivery, compared with 87% of healthy women 
(n = 113). After 6 weeks and 3 months in the group of 
women with epilepsy, these rates decrease to 38.2% and 
36.2%, respectively, and after 6 months the decrease was 
even more visible. Only 18.6% of women with epilepsy 
continued breastfeeding. The above studies show that 
women with epilepsy are less likely to breastfeed than 
women without epilepsy. However, if they start breast-
feeding, after three months they continue in a similar 
percentage as women without epilepsy – 34.5% and 
28.6% respectively (breastfeeding only). It is for this 
reason that the educational aspect encouraging wom-
en with epilepsy to breastfeed is so important (Gerard 
and Pennell, 2019).
In Norway, approximately 90% of women start 
breastfeeding. After 6 months, the percentage of breast-
feeding women in the groups with epilepsy and poly-
therapy was < 50%, in the group with LTG monother-
apy – < 60% and in the group with other AED mono-
therapies the control group (mothers without epilepsy) 
– < 70%. The results may indicate that both mothers and 
their doctors were concerned about the safety of feeding 
while using a particular treatment (Veiby et al., 2015).
The breastfeeding rate for mothers with epilepsy 
in China in the study by Hao et al. (2017) was 59.4%, 
whereas in the healthy women population it was 95%. 
After three months, only 36.3% of mothers exclusively 
breastfed and 49.5% of women with epilepsy stopped 
breastfeeding. After six months, approximately only 
one-third (33.1%) continued breastfeeding their chil-
dren, and 12.8% were exclusively breastfed (Hao et al., 
2017). In contrast, in the Bhutan kingdom, a majority 
of women (97%) reported breastfeeding in the ques-
tionnaire survey (Halani et al., 2017).
In Poland, the work of Bosak et al. (2019) shows that 
in a group of 171 women with epilepsy, breastfeeding 
at any time was reported by 68.1%.
Antiepileptic drugs use safety
Exposure to AEDs through breast milk can potential-
ly cause adverse effects or negatively affect the child’s 
development. Most studies on the transfer of AEDs to 
breast milk indicate that the drug concentration in the 
serum of the infant is well below the pharmacological 
effect limit.
As mentioned above, some drugs such as PB, BDZ, 
LTG and ESM can achieve high concentrations in the 
serum of breastfed infants. Therefore, breastfed infants 
should be monitored for adverse effects. However, ad-
verse effects are still rarely reported in infants who are 
breastfed by mothers taking AEDs. Prospective stud-
ies have not show any negative developmental effects 
in children who were exposed to AEDs through their 
breast milk.
The degree of exposure of the baby to the drugs in 
the mother’s milk can be minimized by breastfeeding 
during periods when the concentration in the milk is 
low, reducing the maternal AED dose to pregnancy lev-
els. Most AEDs are considered safe or moderately safe 
during breastfeeding. Mothers with epilepsy should be 
encouraged to breastfeed, provided that their children 
are carefully monitored.
Long-term effects of antiepileptic drugs’ use 
during breastfeeding
As emphasized earlier breastfeeding has beneficial ef-
fects, but there are concerns that breastfeeding during 
maternal AED therapy may be harmful to the child’s 
development in the long-term perspective. In 2010, Me-
ador et al. published a report on the neurological de-
velopment of children breastfed by mothers with epi-
lepsy. Eighty four breastfed newborns were assessed for 
3 to 24 months (average of 6 months) compared with 
115 non-breastfed newborns. The results showed that 
at 3 years of age, the average IQ in the breastfed group 
was 99 compared to 98 in the non-breastfed group. The 
conclusion was that in the study assessing the intelli-
gence quotient in children of mothers with epilepsy tak-
ing AEDs and breastfeeding their children, at the age of 
3, no negative effects of drugs such as CBZ, LTG, PHT 
or VPA used during breastfeeding were found. Consid-
ering the fact that the intelligence quotient at the age of 
6 allows better prediction of school results, the impact 
of the exposure to AED through breastfeeding on the 
cognitive functions of children at the age of 6 was ex-
amined. The study was conducted as a prospective ob-
servational multicentre study assessing the long-term 
neurodevelopmental effects of using AEDs. Pregnant 
women with epilepsy receiving monotherapy (CBZ, 
LTG, PHT or VPA) were registered from October 14, 
Breastfeeding in epilepsy – recommendations
20
1999 to April 14, 2004 (for 3.5 years) in the United States 
and Great Britain. At 6 years of age, the neurological 
status was assessed in 181 children born to those moth-
ers for whom breastfeeding, and IQ data were availa-
ble. All mothers included in this analysis continued to 
take the AED after delivery. A total of 42.9% of children 
were breastfed for an average of 7.2 months.
The indicators and duration of breastfeeding did 
not differ between the AED drug groups. Researchers 
evaluated the IQ in children aged 6 years who were ex-
posed to the effects of AEDs. Linear regression analysis 
included the adjustment for other known factors that 
could affect the IQ results, including maternal intelli-
gence quotient, specific AED monotherapy, drug dose, 
and folate use prior to pregnancy.
The IQ score was 4 points higher in the group of 
breastfed children compared to those who were not 
breastfed. In the remaining cognitive domains, only 
verbal skills differed significantly between breastfed 
and non-breastfed groups (p  =  0.03). Thus, no negative 
effects of AED exposure through breast milk during 
breastfeeding were observed in six-year-old children, 
which is consistent with another recent study which 
studied 3 year old children (Meador et al., 2014; Mea-
dor et al., 2010).
The study by Veiby et al. (2013) may also provide 
additional evidence that long-term breastfeeding by 
mothers receiving AEDs is safe and even beneficial for 
their offspring. The development of motor skills and 
behaviour was assessed in a group of 223 infants of 
mothers receiving AEDs (CBZ, LTG, VPA). At the age 
of 6 months, impairment of motor skills was noted in 
11.5% of offspring exposed to an AED, much more than 
in the reference group without epilepsy (4.8%). Howev-
er, a reduced risk of impaired motor skills was observed 
in mothers nursing for 6 months when compared to 
the group of women who had stopped feeding before 
the age of 6 months. Infants who were breastfed for six 
months or more experienced greater weight gain and 
did not have as many autistic traits as the group breast-
fed for less than six months. The next assessments car-
ried out at the age of 18 and 36 months did not show 
a negative impact of AEDs taken by the mother on the 
development of children in comparison with the group 
of children of healthy mothers.
It is worth emphasizing that in the study by Veiby et 
al. (2013) the mother’s IQ was not controlled and their 
results were based on the mother’s report; children were 
not individually examined as in the NEAD study. These 
positive effects of breastfeeding babies of mothers with 
epilepsy are consistent with the three latest large pro-
spective cohort studies in the general population (Ber-
nard et al., 2013; Belfort et al., 2013; Julvez et al., 2014). 
These studies found a significant relationship between 
the length of breastfeeding and subsequent positive psy-
chosocial or emotional development of the child.
While the impact of breastfeeding on cognitive func-
tions remains controversial (Jain et al., 2002; Walfisch 
et al., 2013), the presented study results may confirm 
the causal relationship between natural feeding and the 
improvement of the child’s cognitive functions (Chris-
takis, 2013). Questions arise – is there a positive effect 
of feeding on cognitive deficits caused by the AED ef-
fect? Could breastfeeding be a modifiable factor in 
improving cognitive performance in children born to 
mothers who must take AEDs during pregnancy? The 
authors interpret their results carefully, emphasizing 
safety rather than the benefits of breastfeeding in this 
aspect. Nevertheless, the most important and safe in-
terpretation of the above results is that breastfeeding is 
safe for women undergoing an AED monotherapy and 
should be strongly supported by neurologists, obstetri-
cians, neonatologists and paediatricians.
Interesting research results were presented by Dan-
ish authors Sun et al. (2011) asking the question whether 
breastfeeding can reduce the risk of childhood epilep-
sy. The study investigated, based on the Danish birth 
register, 69 750 children born between 1997–2003. The 
study ended in 2008. Information on breastfeeding was 
provided by mothers during two computer-assisted tele-
phone interviews at 6 and 18 months after birth. Infor-
mation on epilepsy (hospitalized and outpatient pa-
tients) was obtained from the Danish national hospital 
register. The authors of this study showed that breast-
feeding was associated with a reduced risk of epilep-
sy. Children breastfed for 3 to 5; 6 to 8; 9 to 12 and ≥13 
months were 26, 39, 50 and 59%, respectively, less likely 
to develop epilepsy after the first year of life when com-
pared to children breastfed for less than a month. This 
favourable trend continued even when children who 
had adverse effects in the neonatal period or children 
who were exposed to adverse effects during pregnancy 
were excluded. The observed beneficial, protective ef-
fect of breastfeeding may be completely random, never-
theless it is another reason to encourage breastfeeding.
It seems that the percentage of foetal malformations 
after exposure to AEDs in the uterus cannot be extrap-
olated to breastfeeding after delivery. Exposure to val-
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proic acid during foetal organogenesis carries a much 
greater risk than during breastfeeding. Therefore, it is 
prudent to plan the safest drug before pregnancy in 
terms of the risk of potential teratogenicity and breast-
feeding if a woman so wishes.
One should be aware of the limitations of studies as 
they involve a small number of patients. There are no 
data on the concentrations of the drug in breast milk 
or in the blood of children, there is also no randomi-
zation and no control group. Only the inclusion of all 
these factor in the analysis can allow a full estimation 
of the data on the safety of AEDs during breastfeeding. 
Previous studies do not provide a definitive answer, but 
there is agreement among epileptologists that we rec-
ommend breastfeeding to mothers with epilepsy while 
informing them about the risks and benefits.
rECOmmENDATIONS
•	 It is recommended that women with epilepsy breast-
feed exclusively for the first 6 months after delivery 
and then continue breastfeeding until at least 12 
months of the child’s age, with the gradual introduc-
tion of complementary foods. It is worth remember-
ing that in infants with a high demand for iron, it is 
appropriate to introduce complementary foods (af-
ter 4 months) – a vegetable soup.
•	 Most AEDs are safe or moderately safe during lac-
tation
•	  AED permeation into milk is inversely proportion-
al to their binding to plasma proteins.
•	 In case of new AEDs, knowledge about the drug me-
tabolism in newborns is required
•	 Neonates should be monitored for drowsiness, re-
duced suckling activity and poor weight gain, es-
pecially in the population of premature newborns
•	 In the event of suspicion of any adverse effects as-
sociated with the mother’s AED intake, it is recom-
mended to monitor the drug’s concentration in the 
infant’s blood. Feeding should be recommended at 
the time of the lowest concentration of the drug in 
the mother’s blood, i.e. ingesting the drug immedi-
ately after feeding or before the newborn’s longest 
period of sleep.
•	 With increased drug effects in the infant, mixed feed-
ing should be considered, i.e. with milk from a breast 
milk bank (if possible) or with ready-made milk. It 
may also be useful to plan a breastfeeding break to 
see if the symptoms disappear and then resurface 
when breastfeeding is resumed. In such cases, it is 
necessary to maintain lactation in the mother by sys-
tematically pumping off milk. The real risk of moth-
er discontinuing breastfeeding should be considered.
•	 The adopted model of feeding a child in every situ-
ation must be agreed with the parents and accept-
ed by them.
•	 In the postpartum period, adjustment of the moth-
er’s dose should be considered if the dose was in-
creased or decreased during pregnancy.
•	 Feeding safety aspects should be discussed.
•	 The following subjects should be discussed: risk of 
postpartum depression, insomnia, compliance with 
the physician’s AED intake recommendations. Med-
ical procedures for women giving birth and during 
delivery may not interfere with the prescribed times 
for taking AEDs. This means that AEDs intake does 
not interfere with the fasting recommendation.
•	 A woman with epilepsy while in the maternity ward 
or neonatology ward should be under increased care 
and observation, in particular under the direct su-
pervision of staff or relatives while using the bath-
room. She should not leave the ward without in-
forming the staff.
management of a nursing mother taking AEDs – 
specific situations
1. Mother with epilepsy, not taking AEDs and with no 
seizures during pregnancy:
•	 a healthy child can stay with the mother in the room-
ing-in system,
•	 sleep deprivation should be prevented, which means 
uninterrupted sleep of the mother between 2–6 AM, 
the last breastfeeding is carried out around midnight, 
the next one on the next day after 6 o’clock; during 
that time the child is in the neonatal ward; it is rec-
ommended to secure pumped-off breast milk for 
night feeding, in individual cases night feeding di-
rectly from the breast is allowed, after determining 
the degree of risk and in consultation with the moth-
er; the mother does not leave the bed;
•	 medical staff hands over and collects the child and 
conducts general supervision of the feeding,
•	 the mother should feed while lying down on a bed 
equipped with safety rails.
2. Mother with epilepsy, taking AEDs with no seizures 
during pregnancy:
•	 a healthy child can stay with the mother in the room-
ing-in system,
•	 sleep deprivation should be prevented, which means 
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uninterrupted sleep of the mother between 2–6 AM, 
the last breastfeeding is carried out around mid-
night, the next one on the next day after 6 o’clock; 
during that time the child is in the neonatal ward; it 
is recommended to secure pumped-off breast milk 
for night feeding,
•	 the mother should feed while lying down on a bed 
equipped with safety rails, it is recommended to 
monitor the newborn in terms of suckling efficien-
cy and effectiveness.
3. Mother with epilepsy, taking AED and with seizures 
during pregnancy:
•	 a healthy child stays with their mother in the pres-
ence of third parties (family, medical staff); they 
spend the remaining time in the neonatology ward,
•	 sleep deprivation should be prevented, which means 
uninterrupted sleep of the mother between 2–6 AM, 
the last breastfeeding is carried out around mid-
night, the next one on the next day after 6 o’clock; 
during that time the child is in the neonatal ward; it 
is recommended to secure pumped-off breast milk 
for night feeding,
•	 the mother should feed while lying down on a bed 
equipped with safety rails, it is recommended to 
monitor the newborn in terms of suckling efficien-
cy and effectiveness.
4. Mother with epilepsy, unknown course of the dis-
ease (no reliable data available):
•	 a healthy child stays with their mother in the pres-
ence of third parties (family, medical staff); they 
spend the remaining time in the neonatology ward,
•	 sleep deprivation should be prevented, which means 
uninterrupted sleep of the mother between 2–6 AM, 
the last breastfeeding is carried out around mid-
night, the next one on the next day after 6 o’clock; 
during that time the child is in the neonatal ward; it 
is recommended to secure pumped-off breast milk 
for night feeding,
•	 the mother should feed while lying down on a bed 
equipped with safety rails, it is recommended to 
monitor the newborn in terms of suckling efficien-
cy and effectiveness.
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